COMMUNIQUÉS West-GlobeNewswire

CMR Surgical receives CE Mark for use of Versius in paediatric surgery
08/01/2026
Small, modular design of the Versius system supports use in robotic-assisted paediatric surgery Cambridge, UK – 8 January 2026, CMR Surgical (‘CMR’ or ‘the Company’), the global surgical robotics business, today [...]
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
08/01/2026
Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to [...]
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
08/01/2026
Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China New five-year data on vamorolone highlighted substantially improved safety [...]
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
08/01/2026
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) announces the pricing of its previously announced public offering of 1,945,000 [...]
Conavi Medical Corp. Announces Filing of Amended & Restated Final Prospectus
08/01/2026
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES A&R FINAL PROSPECTUS WILL BE ACCESSIBLE ON SEDAR+ TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI [...]
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
08/01/2026
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
Alumis Announces Pricing of Upsized Public Offering of Common Stock
08/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated [...]
Best Oral Peptides for Weight Loss: Injectable vs Sublingual vs Daily Pill – Direct Meds Consumer Analysis
08/01/2026
January 2026 Wellness Season: Format Comparison for Needle-Free GLP-1 Options, Administration Preferences, and Telehealth Access Pathways HOUSTON, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for [...]
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
07/01/2026
- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates [...]
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
07/01/2026
Informations Réglementées Châtillon, France, le 7 janvier (22 h 00 CET) 2026 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT [...]
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
07/01/2026
AMF Regulated Information Châtillon, France, January 7, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a [...]
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
07/01/2026
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
07/01/2026
BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc . (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today [...]
Genelux Corporation Announces Proposed Public Offering of Common Stock
07/01/2026
WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten [...]
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 [...]
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL [...]
Sanara MedTech Inc. Receives Innovative Technology Contract from Vizient for BIASURGE® Advanced Surgical Solution
07/01/2026
Contract awarded for products that bring improvement to the healthcare industry FORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) ( [...]
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
NOVATO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra [...]

Pages